Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Sedana Medical

10,02 SEK

+0,60 %

Mindre end 1K følgere

SEDANA

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
+0,60 %
-0,60 %
-26,11 %
-17,46 %
-47,48 %
-21,23 %
-49,11 %
-84,67 %
+68,40 %

Sedana Medical operates in the medical technology industry and focuses on the development and manufacture of systems for inhalation anesthesia. The company's products are aimed at healthcare institutions and anesthesiologists. The business is global with a main presence in Europe, North America and Asia. Sedana Medical was founded in 2005 and is headquartered in Danderyd, Sweden.

Læs mere
Markedsværdi
995,36 mio. SEK
Aktieomsætning
1,06 mio. SEK
Omsætning
178,75 mio.
EBIT %
-28,4 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
12.2
2026

Årsrapport '25

23.4
2026

Delårsrapport Q1'26

27.5
2026

Generalforsamling '26

Alle
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelse24.11.2025, 07.00

Sedana Medical reports positive pre-NDA meeting with FDA

Sedana Medical
Selskabsmeddelelse24.10.2025, 05.00

Sedana Medical AB’s Interim report January-September 2025

Sedana Medical
Selskabsmeddelelse16.10.2025, 16.00

Sedana Medical’s Nomination Committee for the 2026 Annual General Meeting

Sedana Medical

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse10.10.2025, 06.00

Invitation to presentation of Sedana Medical’s interim report for the third quarter 2025

Sedana Medical
Selskabsmeddelelse18.7.2025, 05.00

Sedana Medical AB’s Interim report January-June 2025

Sedana Medical
Pressemeddelelse16.7.2025, 06.00

Sedana Medical's paediatric study published in The Lancet

Sedana Medical
Pressemeddelelse4.7.2025, 06.00

Invitation to presentation of Sedana Medical’s interim report for the second quarter 2025

Sedana Medical
Pressemeddelelse10.6.2025, 06.00

Both of Sedana Medical´s pivotal US studies meet first key secondary endpoint

Sedana Medical
Selskabsmeddelelse15.5.2025, 15.00

Report from Sedana Medical AB’s annual general meeting on 15 May 2025

Sedana Medical
Selskabsmeddelelse6.5.2025, 05.00

Sedana Medical AB’s Interim report January-March 2025

Sedana Medical
Pressemeddelelse25.4.2025, 07.30

Invitation to presentation of Sedana Medical’s interim report for the first quarter 2025

Sedana Medical
Pressemeddelelse23.4.2025, 06.00

Sedana Medical Receives FDA Approval for Early Access Program in the U.S.

Sedana Medical
Selskabsmeddelelse15.4.2025, 06.00

Notice of Annual General Meeting in Sedana Medical

Sedana Medical
Selskabsmeddelelse10.4.2025, 15.32

Sedana Medical publishes its Annual Report for 2024

Sedana Medical
Pressemeddelelse19.3.2025, 10.18

Invitation to investor call related to the SESAR study results

Sedana Medical
Pressemeddelelse18.3.2025, 10.06

Sedana Medical comments on publication of Investigator Initiated Study results (SESAR)

Sedana Medical
Pressemeddelelse17.2.2025, 07.33

Redeye: Sedana Medical Q4 - Slightly better than expected

Sedana Medical
Selskabsmeddelelse13.2.2025, 06.00

Sedana Medical AB’s Year-end report 2024

Sedana Medical
Selskabsmeddelelse12.2.2025, 16.30

Sedana Medical announces positive high-level results also for its second pivotal trial in the United States

Sedana Medical
Selskabsmeddelelse3.2.2025, 16.30

Sedana Medical receives an additional year of market protection for Sedaconda® (isoflurane)

Sedana Medical
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.